• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Binding of the sialic acid-binding lectin, Siglec-9, to the membrane mucin, MUC1, induces recruitment of β-catenin and subsequent cell growth.唾液酸结合凝集素 Siglec-9 与膜粘蛋白 MUC1 的结合诱导 β-连环蛋白的募集和随后的细胞生长。
J Biol Chem. 2013 Nov 1;288(44):31842-52. doi: 10.1074/jbc.M113.471318. Epub 2013 Sep 17.
2
The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9.黏蛋白MUC1通过凝集素Siglec-9的结合来调节肿瘤免疫微环境。
Nat Immunol. 2016 Nov;17(11):1273-1281. doi: 10.1038/ni.3552. Epub 2016 Sep 5.
3
Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.肿瘤相关配体与髓单核细胞唾液酸结合免疫球蛋白样凝集素(Siglecs)的相互作用调节了对癌症的先天免疫反应。
Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14211-6. doi: 10.1073/pnas.1409580111. Epub 2014 Sep 15.
4
A soluble form of Siglec-9 provides an antitumor benefit against mammary tumor cells expressing MUC1 in transgenic mice.可溶性形式的 Siglec-9 可针对表达 MUC1 的乳腺肿瘤细胞提供抗肿瘤益处,在转基因小鼠中。
Biochem Biophys Res Commun. 2014 Jul 18;450(1):532-7. doi: 10.1016/j.bbrc.2014.06.009. Epub 2014 Jun 9.
5
Expression of ligands for Siglec-8 and Siglec-9 in human airways and airway cells.唾液酸结合免疫球蛋白样凝集素8(Siglec-8)和唾液酸结合免疫球蛋白样凝集素9(Siglec-9)的配体在人体气道及气道细胞中的表达
J Allergy Clin Immunol. 2015 Mar;135(3):799-810.e7. doi: 10.1016/j.jaci.2015.01.004.
6
Galectin-3 binds to MUC1-N-terminal domain and triggers recruitment of β-catenin in MUC1-expressing mouse 3T3 cells.半乳糖凝集素-3与MUC1的N端结构域结合,并在表达MUC1的小鼠3T3细胞中触发β-连环蛋白的募集。
Biochim Biophys Acta. 2014 Jun;1840(6):1790-7. doi: 10.1016/j.bbagen.2014.02.008. Epub 2014 Feb 18.
7
Studies on the Detection, Expression, Glycosylation, Dimerization, and Ligand Binding Properties of Mouse Siglec-E.小鼠唾液酸结合免疫球蛋白样凝集素-E的检测、表达、糖基化、二聚化及配体结合特性研究
J Biol Chem. 2017 Jan 20;292(3):1029-1037. doi: 10.1074/jbc.M116.738351. Epub 2016 Dec 5.
8
First Evidence for a Role of Siglec-8 in Breast Cancer.Siglec-8在乳腺癌中作用的首个证据。
Int J Mol Sci. 2021 Feb 18;22(4):2000. doi: 10.3390/ijms22042000.
9
Binding of a sialic acid-recognizing lectin Siglec-9 modulates adhesion dynamics of cancer cells via calpain-mediated protein degradation.唾液酸识别凝集素 Siglec-9 的结合通过钙蛋白酶介导的蛋白降解调节癌细胞的黏附动力学。
J Biol Chem. 2013 Dec 6;288(49):35417-27. doi: 10.1074/jbc.M113.513192. Epub 2013 Oct 21.
10
Siglec Signaling in the Tumor Microenvironment.肿瘤微环境中的 Siglec 信号通路。
Front Immunol. 2021 Dec 13;12:790317. doi: 10.3389/fimmu.2021.790317. eCollection 2021.

引用本文的文献

1
Unraveling the glyco-immunity nexus in pancreatic cancer.解析胰腺癌中的糖免疫关系
Mol Cancer. 2025 Aug 4;24(1):211. doi: 10.1186/s12943-025-02417-4.
2
The role of glycan-lectin interactions in the tumor microenvironment: immunosuppression regulators of colorectal cancer.聚糖-凝集素相互作用在肿瘤微环境中的作用:结直肠癌的免疫抑制调节因子
Am J Cancer Res. 2025 Apr 15;15(4):1347-1383. doi: 10.62347/WBJL4045. eCollection 2025.
3
Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy.黏蛋白1作为癌症免疫治疗和靶向治疗的潜在分子。
J Cancer. 2024 Jan 1;15(1):54-67. doi: 10.7150/jca.88261. eCollection 2024.
4
Sialic Acids on Tumor Cells Modulate IgA Therapy by Neutrophils via Inhibitory Receptors Siglec-7 and Siglec-9.肿瘤细胞上的唾液酸通过抑制性受体Siglec-7和Siglec-9调节中性粒细胞的IgA疗法。
Cancers (Basel). 2023 Jun 29;15(13):3405. doi: 10.3390/cancers15133405.
5
Tamoxifen Modulates the Immune Landscape of the Tumour Microenvironment: The Paired Siglec-5/14 Checkpoint in Anti-Tumour Immunity in an In Vitro Model of Breast Cancer.他莫昔芬调节肿瘤微环境的免疫景观:体外乳腺癌模型中抗肿瘤免疫中的配对 Siglec-5/14 检查点。
Int J Mol Sci. 2023 Mar 14;24(6):5512. doi: 10.3390/ijms24065512.
6
LINC01004-SPI1 axis-activated SIGLEC9 in tumor-associated macrophages induces radioresistance and the formation of immunosuppressive tumor microenvironment in esophageal squamous cell carcinoma.LINC01004-SPI1 轴激活肿瘤相关巨噬细胞中的 SIGLEC9,诱导食管鳞癌的放射抵抗和免疫抑制肿瘤微环境的形成。
Cancer Immunol Immunother. 2023 Jun;72(6):1835-1851. doi: 10.1007/s00262-022-03364-5. Epub 2023 Jan 23.
7
The multifaceted role of MUC1 in tumor therapy resistance.MUC1 在肿瘤治疗耐药中的多效性作用。
Clin Exp Med. 2023 Sep;23(5):1441-1474. doi: 10.1007/s10238-022-00978-y. Epub 2022 Dec 23.
8
Myeloid checkpoints for cancer immunotherapy.癌症免疫治疗的髓系检查点
Chin J Cancer Res. 2022 Oct 30;34(5):460-482. doi: 10.21147/j.issn.1000-9604.2022.05.07.
9
Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy: A Novel Anti-Cancer Strategy With IgA Antibodies?靶向髓系检查点分子联合抗体治疗:IgA 抗体的新型抗癌策略?
Front Immunol. 2022 Jul 5;13:932155. doi: 10.3389/fimmu.2022.932155. eCollection 2022.
10
The Single-Cell Level Perspective of the Tumor Microenvironment and Its Remodeling by CAR-T Cells.肿瘤微环境的单细胞水平视角及其被嵌合抗原受体T细胞(CAR-T细胞)重塑的过程
Cancer Treat Res. 2022;183:275-285. doi: 10.1007/978-3-030-96376-7_10.

本文引用的文献

1
Immunomodulation of monocyte-derived dendritic cells through ligation of tumor-produced mucins to Siglec-9.通过与 Siglec-9 结合肿瘤产生的黏蛋白来调节单核细胞来源的树突状细胞的免疫功能。
Biochem Biophys Res Commun. 2010 Nov 26;402(4):663-9. doi: 10.1016/j.bbrc.2010.10.079. Epub 2010 Oct 29.
2
Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis.循环半乳糖凝集素-3 与肿瘤相关的 MUC1 之间的相互作用增强了肿瘤细胞的同质聚集并阻止了失巢凋亡。
Mol Cancer. 2010 Jun 18;9:154. doi: 10.1186/1476-4598-9-154.
3
The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms.膜黏蛋白Muc4通过依赖ErbB2和不依赖ErbB2的机制抑制多种损伤诱导的细胞凋亡。
Cancer Res. 2009 Apr 1;69(7):2845-52. doi: 10.1158/0008-5472.CAN-08-2089. Epub 2009 Mar 17.
4
Ligation of tumour-produced mucins to CD22 dramatically impairs splenic marginal zone B-cells.将肿瘤产生的粘蛋白与CD22连接会显著损害脾脏边缘区B细胞。
Biochem J. 2009 Feb 1;417(3):673-83. doi: 10.1042/BJ20081241.
5
MUC1 initiates Src-CrkL-Rac1/Cdc42-mediated actin cytoskeletal protrusive motility after ligating intercellular adhesion molecule-1.在连接细胞间黏附分子-1后,MUC1启动Src-CrkL-Rac1/Cdc42介导的肌动蛋白细胞骨架突出运动。
Mol Cancer Res. 2008 Apr;6(4):555-67. doi: 10.1158/1541-7786.MCR-07-2033.
6
MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling.黏蛋白1癌蛋白在成纤维细胞生长因子受体信号传导激活中发挥作用。
Mol Cancer Res. 2006 Nov;4(11):873-83. doi: 10.1158/1541-7786.MCR-06-0204.
7
Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion.半乳糖凝集素-3与癌症相关的MUC1上的汤姆森-弗里德赖希二糖相互作用会导致癌细胞与内皮细胞的黏附增加。
J Biol Chem. 2007 Jan 5;282(1):773-81. doi: 10.1074/jbc.M606862200. Epub 2006 Nov 7.
8
MUC1 is a novel regulator of ErbB1 receptor trafficking.MUC1是表皮生长因子受体1(ErbB1)受体转运的新型调节因子。
Oncogene. 2007 Mar 15;26(12):1693-701. doi: 10.1038/sj.onc.1209976. Epub 2006 Sep 18.
9
MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin.MUC1癌蛋白可阻断糖原合酶激酶3β介导的β-连环蛋白磷酸化及降解过程。
Cancer Res. 2005 Nov 15;65(22):10413-22. doi: 10.1158/0008-5472.CAN-05-2474.
10
Siglecs--the major subfamily of I-type lectins.唾液酸结合免疫球蛋白样凝集素——I型凝集素的主要亚家族。
Glycobiology. 2006 Jan;16(1):1R-27R. doi: 10.1093/glycob/cwj008. Epub 2005 Jul 13.

唾液酸结合凝集素 Siglec-9 与膜粘蛋白 MUC1 的结合诱导 β-连环蛋白的募集和随后的细胞生长。

Binding of the sialic acid-binding lectin, Siglec-9, to the membrane mucin, MUC1, induces recruitment of β-catenin and subsequent cell growth.

机构信息

From the Department of Molecular Biosciences, Faculty of Life Sciences, Kyoto Sangyo University, Kamigamo-Motoyama, Kita-ku, Kyoto 603-8555, Japan.

出版信息

J Biol Chem. 2013 Nov 1;288(44):31842-52. doi: 10.1074/jbc.M113.471318. Epub 2013 Sep 17.

DOI:10.1074/jbc.M113.471318
PMID:24045940
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3814777/
Abstract

Because MUC1 carries a variety of sialoglycans that are possibly recognized by the siglec family, we examined MUC1-binding siglecs and found that Siglec-9 prominently bound to MUC1. An immunochemical study showed that Siglec-9-positive immune cells were associated with MUC1-positive cells in human colon, pancreas, and breast tumor tissues. We investigated whether or not this interaction has any functional implications for MUC1-expressing cells. When mouse 3T3 fibroblast cells and a human colon cancer cell line, HCT116, stably transfected with MUC1cDNA were ligated with recombinant soluble Siglec-9, β-catenin was recruited to the MUC1 C-terminal domain, which was enhanced on stimulation with soluble Siglec-9 in dose- and time-dependent manners. A co-culture model of MUC1-expressing cells and Siglec-9-expressing cells mimicking the interaction between MUC1-expressing malignant cells, and Siglec-9-expressing immune cells in a tumor microenvironment was designed. Brief co-incubation of Siglec-9-expressing HEK293 cells, but not mock HEK293 cells, with MUC1-expressing cells similarly enhanced the recruitment of β-catenin to the MUC1 C-terminal domain. In addition, treatment of MUC1-expressing cells with neuraminidase almost completely abolished the effect of Siglec-9 on MUC1-mediated signaling. The recruited β-catenin was thereafter transported to the nucleus, leading to cell growth. These findings suggest that Siglec-9 expressed on immune cells may play a role as a potential counterreceptor for MUC1 and that this signaling may be another MUC1-mediated pathway and function in parallel with a growth factor-dependent pathway.

摘要

由于 MUC1 携带多种可能被 siglec 家族识别的唾液酸化糖链,我们研究了 MUC1 结合的 siglec,并发现 Siglec-9 与 MUC1 显著结合。免疫化学研究表明,Siglec-9 阳性免疫细胞与人类结肠、胰腺和乳腺癌组织中的 MUC1 阳性细胞相关。我们研究了这种相互作用是否对表达 MUC1 的细胞具有任何功能意义。当用 MUC1 cDNA 稳定转染的小鼠 3T3 成纤维细胞和人结肠癌细胞系 HCT116 与重组可溶性 Siglec-9 连接时,β-catenin 被募集到 MUC1 C 端结构域,并且在可溶性 Siglec-9 的刺激下以剂量和时间依赖性方式增强。设计了一个 MUC1 表达细胞和 Siglec-9 表达细胞的共培养模型,模拟了肿瘤微环境中表达 MUC1 的恶性细胞和表达 Siglec-9 的免疫细胞之间的相互作用。短暂共孵育 Siglec-9 表达的 HEK293 细胞,但不是模拟的 HEK293 细胞,与 MUC1 表达细胞同样增强了 β-catenin 向 MUC1 C 端结构域的募集。此外,用神经氨酸酶处理 MUC1 表达细胞几乎完全消除了 Siglec-9 对 MUC1 介导的信号的影响。募集的 β-catenin 随后被转运到细胞核,导致细胞生长。这些发现表明,免疫细胞上表达的 Siglec-9 可能作为 MUC1 的潜在共受体发挥作用,并且这种信号可能是 MUC1 介导的另一种途径,与生长因子依赖性途径平行发挥作用。